Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in Advanced PPGL, pNET, VHL Disease-Associated Tumors, wt GIST, or HIF-2α Mutated Cancers
NCT04924075Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Primary completion
- Nov 2032
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of belzutifan in pheochromocytoma, Paraganglioma (PGL), Pancreatic neuroendocrine tumor (PanNET), von Hippel–Lindau disease (VHL), gastrointestinal stromal tumor (GIST), sponsored by Merck & Co.. Started Aug 2021; status: recruiting.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)Pancreatic neuroendocrine tumor (PanNET)von Hippel–Lindau disease (VHL)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04924075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924075.